Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2016 Jul 13

PMID 27402109

Citations 25

Authors

Lomeli R Carpio

Jennifer J Westendorf

Affiliations

Soon will be listed here.

Abstract

The involvement of the epigenome in complex diseases is becoming increasingly clear and more feasible to study due to new genomic and computational technologies. Moreover, therapies altering the activities of proteins that modify and interpret the epigenome are available to treat cancers and neurological disorders. Many additional uses have been proposed for these drugs based on promising preclinical results, including in arthritis models. Understanding the effects of epigenomic drugs on the skeleton is of interest because of its importance in maintaining overall health and fitness. In this review, we summarize ongoing advancements in how one class of epigenetic modifiers, histone deacetylases (Hdacs), controls normal cartilage development and homeostasis, as well as recent work aimed at understanding the alterations in the expression and activities of these enzymes in osteoarthritis (OA). We also review recent studies utilizing Hdac inhibitors and discuss the potential therapeutic benefits and limitations of these drugs for preventing cartilage destruction in OA.

Citing Articles

Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis.

Kawata M, McClatchy D, Diedrich J, Olmer M, Johnson K, Yates J JCI Insight. 2023; 8(17).

PMID: 37681413 PMC: 10544226. DOI: 10.1172/jci.insight.170513.

Osteoarthritis related epigenetic variations in miRNA expression and DNA methylation.

Jin L, Ma J, Chen Z, Wang F, Li Z, Shang Z BMC Med Genomics. 2023; 16(1):163.

PMID: 37434153 PMC: 10337191. DOI: 10.1186/s12920-023-01597-6.

Bioinformatics-based analysis of potential candidates chromatin regulators for immune infiltration in osteoarthritis.

Wang W, Ou Z, Peng J, Wang N, Zhou Y BMC Musculoskelet Disord. 2022; 23(1):1123.

PMID: 36550476 PMC: 9783407. DOI: 10.1186/s12891-022-06098-8.

miR-17-92 cluster in osteoarthritis: Regulatory roles and clinical utility.

Pan X, Cen X, Xiong X, Zhao Z, Huang X Front Genet. 2022; 13:982008.

PMID: 36523768 PMC: 9745093. DOI: 10.3389/fgene.2022.982008.

Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis.

Ohzono H, Hu Y, Nagira K, Kanaya H, Okubo N, Olmer M Ann Rheum Dis. 2022; 82(2):262-271.

PMID: 36109140 PMC: 11005918. DOI: 10.1136/ard-2021-221269.

References

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

Luo J, Su F, Chen D, SHILOH A, Gu W . Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000; 408(6810):377-81. DOI: 10.1038/35042612. View

Mostoslavsky R, Chua K, Lombard D, Pang W, Fischer M, Gellon L . Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006; 124(2):315-29. DOI: 10.1016/j.cell.2005.11.044. View

Wang X, Song Y, Jacobi J, Tuan R . Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 2008; 27(1):40-9. PMC: 3612426. DOI: 10.1080/08977190802625179. View

Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D . AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014; 159(3):558-71. PMC: 4344132. DOI: 10.1016/j.cell.2014.09.049. View

Yuan Z, Guan Y, Chatterjee D, Chin Y . Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005; 307(5707):269-73. DOI: 10.1126/science.1105166. View

Perissi V, Jepsen K, Glass C, Rosenfeld M . Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet. 2010; 11(2):109-23. DOI: 10.1038/nrg2736. View

Bantscheff M, Hopf C, Savitski M, Dittmann A, Grandi P, Michon A . Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011; 29(3):255-65. DOI: 10.1038/nbt.1759. View

Zhong H, Ding Q, Chen W, Luo R . Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation. Int Immunopharmacol. 2013; 17(2):329-35. DOI: 10.1016/j.intimp.2013.06.027. View

10.

Gabay O, Zaal K, Sanchez C, Dvir-Ginzberg M, Gagarina V, Song Y . Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine. 2013; 80(6):613-20. PMC: 4288855. DOI: 10.1016/j.jbspin.2013.01.001. View

11.

Verdin E, Dequiedt F, Kasler H . Class II histone deacetylases: versatile regulators. Trends Genet. 2003; 19(5):286-93. DOI: 10.1016/S0168-9525(03)00073-8. View

12.

Cai D, Yin S, Yang J, Jiang Q, Cao W . Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis. Arthritis Res Ther. 2015; 17:269. PMC: 4583998. DOI: 10.1186/s13075-015-0774-3. View

13.

Shimizu E, Selvamurugan N, Westendorf J, Olson E, Partridge N . HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression. J Biol Chem. 2010; 285(13):9616-9626. PMC: 2843211. DOI: 10.1074/jbc.M109.094862. View

14.

Bradley E, Carpio L, Olson E, Westendorf J . Histone deacetylase 7 (Hdac7) suppresses chondrocyte proliferation and β-catenin activity during endochondral ossification. J Biol Chem. 2014; 290(1):118-26. PMC: 4281714. DOI: 10.1074/jbc.M114.596247. View

15.

Marks P . Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta. 2010; 1799(10-12):717-25. PMC: 4043339. DOI: 10.1016/j.bbagrm.2010.05.008. View

16.

McGee-Lawrence M, McCleary-Wheeler A, Secreto F, Razidlo D, Zhang M, Stensgard B . Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone. 2011; 48(5):1117-26. PMC: 3079070. DOI: 10.1016/j.bone.2011.01.007. View

17.

Westendorf J, Zaidi S, Cascino J, Kahler R, van Wijnen A, Lian J . Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002; 22(22):7982-92. PMC: 134736. DOI: 10.1128/MCB.22.22.7982-7992.2002. View

18.

Gabay O, Sanchez C, Dvir-Ginzberg M, Gagarina V, Zaal K, Song Y . Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. Arthritis Rheum. 2012; 65(1):159-66. PMC: 4095888. DOI: 10.1002/art.37750. View

19.

Lemieux M, Yang X, Jardine K, He X, Jacobsen K, Staines W . The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals. Mech Ageing Dev. 2005; 126(10):1097-105. DOI: 10.1016/j.mad.2005.04.006. View

20.

Lakshmaiah K, Jacob L, Aparna S, Lokanatha D, C Saldanha S . Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 2014; 10(3):469-78. DOI: 10.4103/0973-1482.137937. View